Ernexa Therapeutics (NASDAQ: ERNA) has announced it was selected as one of only ten global companies to participate in the prestigious Japan Entry Acceleration Program (JEAP) by the Japan External Trade Organization (JETRO).
According to Ernexa, JEAP drew approximately 70 regenerative medicine companies from 25 countries, underscoring the competitiveness of the selection process. Ernexa was chosen for its differentiated cell therapy platform and its potential to contribute meaningfully to Japan’s globally recognized regenerative medicine and oncology ecosystem.
In a statement, Sanjeev Luther, president and CEO of Ernexa, commented, “Japan is a world leader in regenerative medicine, supported by a progressive regulatory framework and deep oncology expertise. Participation in JEAP gives us direct access to key stakeholders as we evaluate strategic partnerships, clinical development opportunities and potential pathways to expand our platform internationally. Our ultimate goal is to deliver hope to patients with cancer and autoimmune conditions worldwide.”
